All In Biotech

Drug Trial Radar · NCT03773393

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

May 30, 2019

Primary completion

May 25, 2027

Study completion May 30, 2027

Sponsor

Lead sponsor
Cellenkos, Inc.Industry
Sponsor type
Industry
First posted
Dec 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical research study is to determine whether it is safe and practical to give CK0801 (a Cord blood-derived T-regulatory cell product) to patients with bone marrow failure syndrome. Researchers want to determine the highest possible dose that is safe to be given. Researchers also want to learn if CK0801 may improve the symptoms of bone marrow failure syndrome. Patients enrolled in this study will all have been diagnosed with treatment refractory bone marrow failure syndrome (which includes aplastic anemia, myelodysplastic syndrome, or myelofibrosis). Participants eligible to participate in this study are unable or unwilling to be treated with standard therapy or have failed standard therapy.

Conditions

  • Bone Marrow Disease

Interventions

  • CK0801Biological

    CK0801 (a Cord blood-derived T-regulatory cell product)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Severe Infusion Toxicity as Assessed by CTCAE v4.0Time frame: 24 hours post-intervention
  2. Number of Participants with Regimen Related DeathTime frame: 30 days post-intervention
  3. Number of Participants with Severe Cytokine Release Syndrome (CRS)Time frame: 30 days post-intervention

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sarcoma Oncology Research Center, Cancer Center of Southern California

    Santa Monica, California

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.